MicroOrganoSpheresTM (MOS) can be used in Colorectal Cancer. Studies are being conducted now to assess the ability to generate MOSTM from advanced colon and rectal tumors and perform a drug screen of therapy candidates in <14 days. This will allow for the validation of a diagnostic which can be rapidly used in the clinic to guide therapy for advanced stage patients.
Colorectal cancer is the third most common cancer diagnosed in the United States and the second most common cause of cancer deaths in men and women. It is estimated that there are over 100,000 new cases of colon cancer and 45,000 of rectal cancer reported in 2021. The 5-year relative survival rate for colon cancer and rectal cancer are 63% and 67%, respectively.1 Xilis is developing its proprietary MicroOrganoSphereTM technology as a novel precision oncology platform in colorectal cancer. Below is a list of our recent presentations.
American Cancer Society: https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
Accessed September 2021.